Tumour escape from immune surveillance through dendritic cell inactivation

Seminars in Cancer Biology

Volumn 12, Issue 1, 2002, Pages 33-42

  Vicari, Alain P ^a   Caux, Christophe ^a   Trinchieri, Giorgio ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antigen presenting cells; Chemokines; Dendritic cells; Tumour antigen presentation; Tumour escape

Indexed keywords

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER; CARCINOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; DENDRITIC CELL; DIAGNOSTIC VALUE; HUMAN; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ESCAPE;

EID: 0036153123     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0400     Document Type: Article

References (122)

1. Cancer tumor antigens
2. Dendritic cells and the control of immunity
3. Interleukin-12: A cytokine at the interface of inflammation and immunity
4. The dendritic cell and human cancer vaccines
5. Localization dose and time of antigens determine immune reactivity
6. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer
7. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma
8. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival
9. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
10. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
11. Tumor-infiltrating dendritic cells in neoplasms with a correlation to usual prognostic factors and to clinical outcome
12. Papillary carcinoma of the thyroid: Hepatocyte Growth Factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells
13. Minimal recruitment and activation of dendritic cells within renal cell carcinoma
14. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor
15. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
16. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
17. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
18. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue
19. Clinical significance of defective dendritic cell differentiation in cancer
20. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
21. Regulation of dendritic cell trafficking: A process that involves the participation of selective chemokines
22. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: Perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor
23. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes
24. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
25. The host-tumor immune conflict: From immunosuppression to resistance and destruction
26. Langerhans cells in the TGF beta 1 null mouse
27. Respective involvement of TGF-beta and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors
28. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer
29. Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes
30. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells
31. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes
32. Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells
33. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
34. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
35. Immune surveillance against a solid tumor fails because of immunological ignorance
36. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
37. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
38. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
39. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
40. Amount of interleukin 12 available at the tumor site is critical for tumor regression
41. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154
42. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells
43. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses
44. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
45. How does the immune system distinguish self from nonself?
46. The nature of the principal type 1 interferon-producing cells in human blood
47. Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors
48. Natural interferon alpha/beta-producing cells link innate and adaptive immunity
49. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells
50. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
51. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST1684
52. Natural adjuvants: Endogenous activators of dendritic cells
53. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
54. Antigen presentation to cytotoxic T lymphocytes in vivo
55. Processing of engulfed apoptotic bodies yields T cell epitopes
56. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
57. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
58. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
59. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
60. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
61. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
62. Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo
63. Tumor's other immune targets: Dendritic cells
64. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells
65. Human CD14 mediates recognition and phagocytosis of apoptotic cells
66. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling
67. Fc receptor signaling and trafficking: A connection for antigen processing
68. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
69. Immunosuppressive effects of apoptotic cells
70. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF
71. Effect of interleukin-10 on dendritic cell maturation and function
72. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells
73. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells
74. Induction of tolerance by IL-10-treated dendritic cells
75. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10
76. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
77. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma
78. Human non-small cell lung cancer cells express a type 2 cytokine pattern
79. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response
80. Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions
81. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies
82. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production
83. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients
84. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
85. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production
86. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
87. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration
88. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory
89. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors
90. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells
91. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells
92. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production
93. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: The levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation
94. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2
95. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
96. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
97. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
98. Expression of cyclooxygenase-2 in human gastric carcinoma
99. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
100. Expression of cyclooxygenase-2 in human lung carcinoma
101. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
102. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
103. Cyclooxygenase-2 expression in hepatocellular carcinoma
104. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
105. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
106. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
107. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
108. Tumor suppressor activity of the TGF-beta pathway in human cancers
109. Role of transforming growth factor-beta signaling in cancer
110. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells
111. Tumor gangliosides inhibit the tumor-specific immune response
112. Hormonal carcinogenesis
113. Glucocorticoids affect human dendritic cell differentiation and maturation
114. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3
115. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
116. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts
117. Decreased antigen presentation by dendritic cells in patients with breast cancer
118. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo
119. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
120. Ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis
121. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
122. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization